Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Operations (2020 - 2024)

Immuneering (IMRX) has 5 years of Cash from Operations data on record, last reported at 14510513.0 in Q4 2024.

  • For Q4 2024, Cash from Operations fell 23.23% year-over-year to 14510513.0; the TTM value through Dec 2024 reached 54999571.0, down 12.32%, while the annual FY2024 figure was 54999571.0, 12.32% down from the prior year.
  • Cash from Operations reached 14510513.0 in Q4 2024 per IMRX's latest filing, down from 13472024.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3486028.0 in Q3 2020 and bottomed at 15491114.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 10436638.67, with a median of 11137201.5 recorded in 2023.
  • Peak YoY movement for Cash from Operations: tumbled 159.17% in 2021, then dropped 0.23% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 5453116.0 in 2020, then crashed by 69.43% to 9238990.0 in 2021, then fell by 27.16% to 11748614.0 in 2022, then dropped by 0.23% to 11775201.0 in 2023, then decreased by 23.23% to 14510513.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 14510513.0 in Q4 2024, 13472024.0 in Q3 2024, and 11525920.0 in Q2 2024.